Suman Redhu
Novartis (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Multiple Myeloma Research and Treatments, Peptidase Inhibition and Analysis
Most-Cited Works
- → Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study(2014)438 cited
- → A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas(2014)357 cited
- → A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)(2015)356 cited
- → Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial(2023)268 cited
- → Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib(2017)220 cited
- → A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer(2012)79 cited
- → Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis(2020)57 cited
- → MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non–small cell lung cancer (NSCLC).(2013)21 cited
- → Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial(2017)21 cited
- → Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).(2017)8 cited